- Eagle Pharmaceuticals has felt the impact of COVID-19, and the earnings reports have reflected that. As a result, the share price has taken a beating over the past year.
- The company expects to see its earnings improve over the remainder of 2021 as the country begins to reopen and patients resume their chemo treatments.
- In addition to being a reopening play, I expect EGRX to be a great growth story in the coming years as they launch PEMFEXY and vasopressin in the coming quarters.
- I discuss my leading downside risk and reveal my plans for establishing a position in EGRX.
For further details see:
Eagle Pharmaceuticals: A Potential Reopening Play